

Sebastian Palmqvist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6829852/publications.pdf>

Version: 2024-02-01

137
papers

11,024
citations

38720

50
h-index

34964

98
g-index

154
all docs

154
docs citations

154
times ranked

8364
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
2	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020, 26, 379-386.	15.2	643
3	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	3.8	640
4	Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	5.8	596
5	Plasma β -amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016, 6, 26801.	1.6	442
6	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016, 87, 1827-1835.	1.5	371
7	CSF A β ₄₂ /A β ₄₀ and A β ₄₂ /A β ₃₈ ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	1.7	329
8	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β -Amyloid 42. <i>JAMA Neurology</i> , 2014, 71, 1282.	4.5	300
9	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	3.8	298
10	Cerebrospinal fluid analysis detects cerebral amyloid- β accumulation earlier than positron emission tomography. <i>Brain</i> , 2016, 139, 1226-1236.	3.7	292
11	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015, 85, 1240-1249.	1.5	288
12	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. <i>JAMA Neurology</i> , 2019, 76, 1060.	4.5	282
13	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1683.	5.8	252
14	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	15.2	236
15	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170.	3.3	228
16	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016, 8, 1184-1196.	3.3	219
17	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
18	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018, 91, e867-e877.	1.5	207

#	ARTICLE	IF	CITATIONS
19	A β deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	4.7	202
20	Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516.	3.7	198
21	Associations between tau, A β , and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019, 92, e601-e612.	1.5	196
22	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 149.	4.5	176
23	¹⁸ F-AV-1451 and CSF τ and β as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	3.3	156
24	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3234-3241.	3.7	150
25	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. <i>Brain</i> , 2017, 140, 2286-2294.	3.7	149
26	Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2019, 76, 1319.	4.5	149
27	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	4.5	148
28	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , 2020, 77, 955.	4.5	136
29	The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 893-901.	1.2	133
30	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.	3.3	122
31	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.	5.8	115
32	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.5	96
33	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.	5.3	94
34	Soluble p-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021, 13, e14022.	3.3	90
35	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. <i>JAMA Psychiatry</i> , 2014, 71, 1183.	6.0	85
36	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85

#	ARTICLE	IF	CITATIONS
37	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83
38	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , 2020, 94, e2233-e2244.	1.5	80
39	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 632.	4.5	80
40	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	2.4	78
41	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021, 144, 2771-2783.	3.7	78
42	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. <i>PLoS ONE</i> , 2012, 7, e38639.	1.1	73
43	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.4	73
44	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1405-1412.	1.3	72
45	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ₄₂ /A β ₄₀ and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.4	72
46	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 149.	4.5	66
47	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021, 144, 2826-2836.	3.7	65
48	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020, 143, 3805-3815.	3.7	65
49	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021, 97, e1681-e1694.	1.5	60
50	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	3.3	58
51	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019, 8, .	2.8	57
52	Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	3.0	56
53	Assessing risk for preclinical β -amyloid pathology with APOE, cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 76-84.	1.2	49
54	Accurate risk estimation of β -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204.	0.4	49

#	ARTICLE	IF	CITATIONS
55	Increased amyloidogenic APP processing in APOE ϵ 4-negative individuals with cerebral β 2-amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918.	5.8	48
56	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. <i>Cerebral Cortex</i> , 2019, 29, 2173-2182.	1.6	39
57	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020, 11, 6252.	5.8	36
58	Association between Subcortical Lesions and Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 417-423.	0.7	33
59	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 41.	3.0	33
60	Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. <i>BMC Neurology</i> , 2013, 13, 140.	0.8	31
61	Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1191-1201.	1.2	31
62	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and β 2 Pathology in Non-demented Individuals. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 306.	1.7	30
63	Brain myoinositol as a potential marker of amyloid-related pathology. <i>Neurology</i> , 2019, 92, e395-e405.	1.5	30
64	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 29.	3.0	29
65	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. <i>Cerebral Cortex</i> , 2018, 28, 340-349.	1.6	28
66	β 2-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , 2019, 9, 11180.	1.6	28
67	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2245-2258.	3.3	27
68	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ϵ 4, sex and age. <i>Progress in Neurobiology</i> , 2021, 198, 101904.	2.8	25
69	Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. <i>Alzheimer's and Dementia</i> , 2023, 19, 797-806.	0.4	24
70	Association of β 2-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. <i>Neurology</i> , 2022, 98, .	1.5	22
71	Cerebral hypoperfusion is not associated with an increase in amyloid β 2 pathology in middle-aged or elderly people. <i>Alzheimer's and Dementia</i> , 2018, 14, 54-61.	0.4	21
72	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. <i>Biological Psychiatry</i> , 2022, 92, 34-43.	0.7	21

#	ARTICLE	IF	CITATIONS
73	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 113-122.	0.6	20
74	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. <i>Current Alzheimer Research</i> , 2012, 9, 257-266.	0.7	17
75	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 46.	3.0	17
76	Association of CSF A β Levels With Risk of Alzheimer Disease-Related Decline. <i>Neurology</i> , 2022, 98, .	1.5	16
77	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90.	1.5	15
78	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 109.	3.0	14
79	Derivation and utility of an A β -PET pathology accumulation index to estimate A β load. <i>Neurology</i> , 2020, 95, e2834-e2844.	1.5	14
80	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 30.	3.0	14
81	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 23, 439-446.	0.9	11
82	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 15417.	1.6	11
83	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. <i>NeuroImage: Clinical</i> , 2020, 27, 102310.	1.4	10
84	Unburdening dementia – a basic social process grounded theory based on a primary care physician survey from 25 countries. <i>Scandinavian Journal of Primary Health Care</i> , 2020, 38, 253-264.	0.6	9
85	A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years. <i>International Psychogeriatrics</i> , 2014, 26, 1493-1500.	0.6	8
86	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 683-691.	1.7	8
87	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders. <i>Movement Disorders</i> , 2022, 37, 993-1003.	2.2	8
88	Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000370.	1.2	7
89	Components of gait in people with and without mild cognitive impairment. <i>Gait and Posture</i> , 2022, 93, 83-89.	0.6	7
90	Biomarker testing in MCI patients – deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	3.0	6

#	ARTICLE	IF	CITATIONS
91	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 19853.	1.6	6
92	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	6
93	Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. <i>Brain</i> , 2016, 139, e61-e61.	3.7	5
94	Coping Styles among People with Parkinson's Disease: A Three-Year Follow-Up Study. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020, 10, 190.	1.0	5
95	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments: EQ-5D data from the Swedish BioFINDER study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1832-1842.	0.4	5
96	Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS). <i>Journal of Pain and Symptom Management</i> , 2020, 60, 346-354.e2.	0.6	4
97	Astrocytic function is associated with both amyloid- β^2 and tau pathology in non-demented APOE ϵ_4 carriers. <i>Brain Communications</i> , 2022, 4, .	1.5	4
98	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
99	O1-07-01: Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, P140.	0.4	1
100	DT-02-04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA $A\beta^2$ BIOMARKER ASSAYS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1670.	0.4	1
101	Spatial Distribution of Tau and β^2 -Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes. <i>Neurology</i> , 2021, 96, 191-192.	1.5	1
102	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	1.2	1
103	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid- β^2 pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
104	Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta-amyloid, tau, neurodegeneration, and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
105	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
106	P2-290: BIOMARKERS FOR IDENTIFYING NEURODEGENERATIVE DISORDERS EARLY AND RELIABLY (BIOFINDER): METHODOLOGY AND PRELIMINARY RESULTS OF A NEW LARGE PROSPECTIVE COHORT STUDY. , 2014, 10, P583-P584.		0
107	O2-08-06: CSF Analysis Detects Cerebral β^2 Amyloid Accumulation Earlier than Amyloid Pet. <i>Alzheimer's and Dementia</i> , 2016, 12, P246.	0.4	0
108	[P3-284]: THE MONTREAL COGNITIVE ASSESSMENT: NORMATIVE DATA FROM A LARGE SWEDISH POPULATION-BASED COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1051.	0.4	0

#	ARTICLE	IF	CITATIONS
109	[O2â€“01â€“02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSSâ€“VALIDATED METHOD THAT PREDICTS CEREBRAL Î²â€“AMYLOIDOSIS. Alzheimer's and Dementia, 2017, 13, P548.	0.4	0
110	P3â€“492: THE MISINTERPRETED AGE EFFECT ON COGNITIVE TEST RESULTS: A PRESENTATION OF TEST NORMS FROM PERSONS WITHOUT UNDERLYING PATHOLOGIES. Alzheimer's and Dementia, 2018, 14, P1310.	0.4	0
111	P4â€“078: CONCORDEâ€“AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1465.	0.4	0
112	O3â€“14â€“05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1061.	0.4	0
113	DTâ€“01â€“06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS. Alzheimer's and Dementia, 2018, 14, P1667.	0.4	0
114	P1â€“430: EFFECTS OF <i>APOE</i> Îµ4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.4	0
115	O2â€“15â€“04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
116	F1â€“04â€“01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€“DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P206.	0.4	0
117	P1â€“373: Î²ETAâ€“AMYLOID AND WHITE MATTER LESIONS ARE INDEPENDENTLY ASSOCIATED WITH HIPPOCAMPAL ATROPHY AND REDUCED CORTICAL TEMPORAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P439.	0.4	0
118	O3â€“04â€“01: ASSOCIATIONS BETWEEN TAU, AÎ² AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1018.	0.4	0
119	ICâ€“Pâ€“036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€“DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.4	0
120	O2â€“09â€“01: CSF, PLASMA AND MRI BIOMARKER TRAJECTORIES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P641.	0.4	0
121	DTâ€“01â€“04: DIAGNOSTIC PERFORMANCE OF [¹⁸ F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€“2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.4	0
122	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that are impacted by APOE Îµ4, sex and age but not pathology. Alzheimer's and Dementia, 2020, 16, e040745.	0.4	0
123	Genomeâ€“wide polygenic risk scores for identification of gene therapeutic target. Alzheimer's and Dementia, 2020, 16, e040903.	0.4	0
124	Health utility in preclinical and prodromal AD compared to controls: EQ5D data from the Swedish Biofinder Study. Alzheimer's and Dementia, 2020, 16, e041032.	0.4	0
125	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.4	0
126	Ability of tauâ€“PET, phosphoâ€“tau217, NfL and cortical thickness to predict shortâ€“term cognitive decline in early symptomatic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
127	Unravelling drivers of age- and beta-amyloid-related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
128	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
129	Tau and synaptic biomarkers but not amyloid β are associated with cerebral perfusion in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
130	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
131	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
132	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid $\text{P}\tau_{181}$, $\text{P}\tau_{217}$ and $\text{P}\tau_{231}$ assays. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
133	Amyloid β accumulation is independently related to executive function in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
134	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
135	The association between diet in mid-life and dementia incidence over a 20-year period. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
136	Potential drivers of age- and beta-amyloid-related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
137	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053556.	0.4	0